Turning your Life Sciences leads into long-term commercial value
Learn how aligning content, channels and automation through lead mapping can unlock better performance across the funnel.
Sapphire Digital Health Advisory joins Cambridge Network
Sapphire Digital Health Advisory Ltd is pleased to join Cambridge Network as part of our commitment to collaboration, innovation and responsible digital health transformation.
Qureight to support Mediar Therapeutics’ Phase 2 trial of MTX-474 in diffuse cutaneous Systemic Sclerosis
Qureight’s AI-powered quantitative imaging analytics platform and services to analyse HRCT images to evaluate changes in compartment-specific lung biomarkersThe focus of these efforts will be on the quantitative assessment of change from baseline in lung fibrosis
Reduce sickness absence, retain staff and increase productivity in your business
As it is Mental Health Awareness Week, it’s a perfect opportunity for me to reintroduce myself.
Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001
First investigational inhaled ENaC blocker to deliver clinically relevant and statistically significant change in lung function compared to placebo Inhaled therapeutic designed to treat the 10% of people with cystic fibrosis with the highest unmet medical need
Alfa Corporate Finance advises on the sale of Cambridge based Blue Scientific to Aptco Group
Alfa Corporate Finance has advised on the sale of BlueScientific to Aptco Group, supporting the shareholders from initial strategic review through to buyer selection, negotiation and completion. The transaction enables BlueScientific to join a broader pan-European platform while retaining leadership continuity, and was structured to balance value, cultural alignment and long-term growth.
How IT directors can finally get ahead of tickets
Is your ticket queue ever truly completed?Or is it just quiet enough for you to breathe before the next wave hits?
From where we sit, tickets are rarely the real problem. They’re the visible symptom.
A weekend in Cambridge - Exclusive for families and partners of The University Arms and Cambridge Network
University Arms Cambridge is opening its doors to the families and guests of our corporate partners. Indulge with 30% off B&B on Friday, Saturday, and Sunday nights, a welcome drink on arrival, and breakfast included. Available by invitation only. Email [email protected] to book.
Nuclera launches antibody triage service to advance AI-driven antibody discovery
Rapid binder triage, of AI-driven candidate sets, enables early elimination of non-binders ahead of costly downstream workflowsPowered by cell-free technology to convert AI-generated candidates into experimental binding dataCambridge, UK and Bo
Guardtech unveil revamped Isopod Configurator online cleanroom pod builder tool
The East Anglian cleanroom construction specialists have given their revolutionary ‘build your own cleanroom’ software a facelift to further enhance users’ procurement journey
Cambridge NeuroWorks named “Tech for Good” winner for advancing breakthrough neurotechnology
Cambridge NeuroWorks has been named winner of the “Tech for Good” Award at the Cambridge Independent Science & Technology Awards 2026, recognising its rapid progress in accelerating breakthrough neurotechnologies with the potential to transform millions of lives.
Cambridge University Hospitals announces Nicola Ayton as Chief Executive
Cambridge University Hospitals NHS Foundation Trust (CUH) has appointed Nicola Ayton as Chief Executive, following a competitive recruitment process. She had been serving as interim Chief Executive since 1 January 2026.
Nuala McBride joins Salus Wellness
Nuala McBride is a degree-qualified nutritionist registered under the UK's Association for Nutrition.
Clement Mind presents at UKABIF 2026: Managing Challenging Behaviours after Acquired Brain Injury
Dr Alberto Bonilla Miralles, Clinical & Occupational Psychologist and Director at Clement Mind, delivered a specialist presentation at the UK Acquired Brain Injury Forum (UKABIF) on evidence-based approaches to understanding and managing challenging behaviours following an acquired brain injury.
12 gene therapies converge on retinitis pigmentosa and a $3.4bn market by 2033
This month Gene Scope Intelligence (www.genescope-intelligence.com), a dedicated gene therapy market intelligence platform releases a brand new commercial analysis and demand forecast for new gene therapies directed at Retinitis Pigmentosa (RP).
Calla Lily Clinical Care doses first patients in clinical trial for intravaginal drug delivery platform for threatened miscarriage
FREEDOM study to evaluate progesterone delivery using Callavid intravaginal platformNIHR-funded trial in collaboration with University Hospitals Coventry and Warwickshire NHS TrustLondon, UK, 06 May 2026: Calla Lily Clinical Care, a wo
FUJIFILM Biosciences and NextCell launch new commercial platform comprised of RUO Stromal Cells and Cell Culture Media
Collaboration results in platform to help researchers overcome challenges in MSC research
Bio-Rad expands range of TrailBlazer Kits for Antibody Conjugation to StarBright Dyes
Expanded Range Increases Access to Bio-Rad’s StarBright™ Dyes for Flow Cytometry and Western Blot Applications in Immunology Research
Beware the next generation of phishing attacks
If phishing scams are supposed to trick people, why do so many of them still feel clumsy?
For years, the answer was simple: Most scams were mass-produced.
Weight loss drugs boom drives pharma R&D returns, but industry could face ‘bubble’ effect
Top global pharma companies’ return on R&D increased for third consecutive year; Growth is almost entirely driven by GLP-1 drugs - used to treat obesity and diabetes - and accounts for 38% of projected sales;Obesity drugs have displaced oncology dr
Sable&Hawkes deliver new multi-million environment development project for Luton and Dunstable NHS
Client: Bedfordshire Hospitals NHS Foundation Trust Project: New Acute Services & Multi-Ward Block
Innovate Cambridge to recognise a new wave of companies at the Business Weekly Awards
Innovate Cambridge has announced a new award category for this year’s prestigious Business Weekly Awards, recognising a new generation of science and technology companies redefining what successful innovation looks like.
Daniel Zeichner MP welcomes Astrazeneca’s £300 million investment as boost for Cambridge
Daniel Zeichner, MP for Cambridge, has welcomed the announcement made by the Prime Minister, Sir Keir Starmer, during Prime Minister’s Questions today that AstraZeneca will invest £300 million into the UK’s life sciences sector.
Lab Thread introduces Unified Lab Software Platform to streamline biological research
Connects scientific teams, data and workflows within a single, fully integrated digital lab management system